

09-J2000-92

Original Effective Date: 1/15/18

Reviewed: 01/12/22

Revised: 02/15/22

Subject: Benralizumab (Fasenra)

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Dosage/ Administration	Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions
Related Guidelines	Other	References	Updates		

DESCRIPTION:

Benralizumab (Fasenra™), a humanized IL-5 receptor alpha-directed cytolytic monoclonal antibody, was approved by the U.S. Food and Drug Administration (FDA) in November 2017 for the add-on maintenance treatment of patients aged 12 years and older with severe asthma with an eosinophilic phenotype. Benralizumab was given an orphan drug designation for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in November 2018.

The safety and effectiveness of benralizumab was established in three double-blind, randomized, placebo-controlled trials in individuals with severe asthma. Study data from SIROCCO and CALIMA demonstrated that add-on benralizumab treatment significantly reduced the annual exacerbation rate and improved lung function compared with placebo in adults and adolescents with severe, uncontrolled asthma with eosinophilic phenotype. Study data from ZONDA showed that benralizumab in adults significantly reduced the glucocorticoid dose from baseline, but found no significant improvement in FEV1 at 28 weeks.

SIROCCO, an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, evaluated the efficacy and safety of benralizumab in patients with severe, uncontrolled asthma with eosinophilia. (n=1205). Participants were required to have a diagnosis of asthma for at least 1 year and have at least two exacerbations while on high-dosage inhaled corticosteroids and long-acting β2-agonists (ICS plus LABA) in the previous year. Patients were randomly assigned (1:1:1) to benralizumab 30 mg either every 4 weeks (Q4W; n=400) or every 8 weeks with the first three doses every 4 weeks (Q8W; n=398) or placebo (n=407) for 48 weeks as add on to their standard treatment. Patients were stratified 2:1 according to blood eosinophil counts of at least 300 cells per μL and less than 300 cells per μL. The primary endpoint was annual exacerbation rate ratio versus placebo, and key secondary endpoints were prebronchodilator FEV1 and total asthma symptom score at week 48, for patients with blood eosinophil counts of at least 300 cells per μL. Efficacy analyses were by intention to treat (based on the full analysis set). Compared with placebo, benralizumab reduced the annual asthma exacerbation rate over 48 weeks

when given Q4W (rate ratio 0.55 [95% CI 0.42-0.71], $p < 0.0001$) or Q8W (rate ratio 0.49 [95% CI 0.37-0.64], $p < 0.0001$). Both benralizumab dosing regimens significantly improved prebronchodilator FEV1 in patients at week 48 compared with placebo (least-squares mean change from baseline: Q4W group 0.106 L [95% CI 0.016-0.196]; Q8W group 0.159 L [95% CI 0.068-0.249]). Compared with placebo, asthma symptoms were improved by the Q8W regimen (least-squares mean difference -0.25 [95% CI -0.45 to -0.06]), but not the Q4W regimen (-0.08 [95% CI -0.27 to 0.12]). The most common adverse events were worsening asthma (105 [13%] of 797 benralizumab-treated patients vs 78 [19%] of 407 placebo-treated patients) and nasopharyngitis (93 [12%] vs 47 [12%]).

CALIMA, a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, evaluated 1306 participants with severe asthma uncontrolled by medium-dosage to high-dosage inhaled corticosteroids plus long-acting β_2 -agonists (ICS plus LABA), elevated blood eosinophil counts, and a history of two or more exacerbations in the previous year. Patients were randomly assigned (1:1:1) to receive 56 weeks of benralizumab 30 mg every 4 weeks (Q4W; $n=425$), benralizumab 30 mg every 8 weeks with the first three doses 4 weeks apart (Q8W; $n=441$), or placebo ($n=440$). Patients were stratified (2:1) by baseline blood eosinophil counts 300 cells per μL or greater and less than 300 cells per μL , respectively. The primary endpoint was annual exacerbation rate ratio versus placebo for patients receiving high-dosage ICS plus LABA with baseline blood eosinophils 300 cells per μL or greater (intention-to-treat analysis). Key secondary endpoints were pre-bronchodilator FEV1 and total asthma symptom score. Benralizumab resulted in significantly lower annual exacerbation rates with the Q4W regimen (rate 0.60 [95% CI 0.48-0.74], rate ratio 0.64 [95% CI 0.49-0.85], $p=0.0018$, $n=241$) and Q8W regimen (rate 0.66 [95% CI 0.54-0.82], rate ratio 0.72 [95% CI 0.54-0.95], $p=0.0188$, $n=239$) compared with placebo (rate 0.93 [95% CI 0.77-1.12], $n=248$). Benralizumab also significantly improved pre-bronchodilator FEV1 (Q4W and Q8W) and total asthma symptom score (Q8W only) in these patients. The most common adverse events were nasopharyngitis (90 [21%] in the Q4W group, 79 [18%] in the Q8W group, and 92 [21%] in the placebo group) and worsening asthma (61 [14%] in the Q4W group, 47 [11%] in the Q8W group, and 68 [15%] in the group).

ZONDA, a 28-week multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, evaluated 220 individuals with severe asthma associated with eosinophilia. Patients received benralizumab 30 mg every 4 weeks (Q4W; $n=72$), benralizumab 30 mg every 8 weeks with the first three doses 4 weeks apart (Q8W; $n=73$), or placebo ($n=75$). The two benralizumab dosing regimens significantly reduced the median final oral glucocorticoid doses from baseline by 75%, as compared with a reduction of 25% in the oral glucocorticoid doses in the placebo group ($P < 0.001$ for both comparisons). The odds of a reduction in the oral glucocorticoid dose were more than 4 times as high with benralizumab as with placebo. Among the secondary outcomes, benralizumab administered every 4 weeks resulted in an annual exacerbation rate that was 55% lower than the rate with placebo (marginal rate, 0.83 vs. 1.83, $p=0.003$), and benralizumab administered every 8 weeks resulted in an annual exacerbation rate that was 70% lower than the rate with placebo (marginal rate, 0.54 vs. 1.83, $p < 0.001$). At 28 weeks, there was no significant effect of either benralizumab regimen on the FEV1, as compared with placebo. The effects on various measures of asthma symptoms were mixed, with some showing significant changes in favor of benralizumab and others not showing significant changes. Frequencies of adverse events were similar between each benralizumab group and the placebo group.

Evidence-based practice guidelines or position statements from the American Academy of Allergy, Asthma and Immunology (AAAAI), European Respiratory Society/American Thoracic Society (ERS/ATS), Global Initiative for Chronic Obstructive Lung Disease (GOLD), and National Heart, Lung and Blood Institute (NHLBI) have not been updated to include recommendations surrounding the use of benralizumab.

POSITION STATEMENT:

Site of Care: If benralizumab (Fasenra) is administered in a hospital-affiliated outpatient setting, additional requirements may apply depending on the member's benefit. Refer to [09-J3000-46: Site of Care Policy for Select Specialty Medications](#).

Initiation of benralizumab (Fasenra) **meets the definition of medical necessity** for members diagnosed with either of the following conditions when ALL associated criteria are met:

1. Severe eosinophilic asthma
 - a. Member's symptoms remain uncontrolled or inadequately controlled despite three months of treatment with at least **ONE** of the following:
 - i. High-dose inhaled corticosteroids (see table 1-3) used in combination with a long-acting beta agonist (e.g., formoterol fumarate (Foradil), salmeterol xinafoate (Serevent))
 - ii. High-dose inhaled corticosteroids (see table 1-3) used in combination with a leukotriene modifier (e.g., montelukast, zafirlukast)
 - iii. High-dose inhaled corticosteroids (see table 1-3) used in combination with theophylline
 - iv. High-dose inhaled corticosteroids (see table 1-3) with daily oral corticosteroids used in combination with at least one additional controller medication (i.e., long-acting beta agonist, leukotriene modifier, theophylline)
 - b. Member has a history of uncontrolled asthma while on asthma control therapy as demonstrated by **ONE** of the following:
 - i. Two or more exacerbations requiring systemic glucocorticoids while being treated with a high-dose inhaled corticosteroid in the past year
 - ii. Serious asthma exacerbations requiring hospitalization, mechanical ventilation, or visit to the emergency room or urgent care within the past 12 months
 - iii. Controlled asthma that worsens when the doses of inhaled and/or systemic corticosteroids are tapered
 - iv. Baseline Forced Expiratory Volume (FEV1) that is less than 80% of predicted
 - c. Member's eosinophil count is at least 150 cells/microliter during the previous six weeks OR at least 300 cells/microliter during the previous year – laboratory documentation must be provided
 - d. Benralizumab is not used in combination with dupilumab (Dupixent), mepolizumab (Nucala), omalizumab (Xolair) or reslizumab (Cinqair)
 - e. Benralizumab is prescribed by a board certified (or board eligible) allergist, immunologist, or pulmonologist
 - f. Dose does not exceed either of the following:
 - i. Initial dose: 30 mg every 4 weeks x 3 doses
 - ii. Maintenance dose: 30 mg every 8 weeks
 - g. Member is 12 years of age or older
2. Eosinophilic granulomatosis with polyangiitis (EGPA)
 - a. Member has relapsing or refractory disease
 - b. Member's diagnosis is confirmed by the presence of **ALL** of the following:

- i. Asthma
- ii. Eosinophilia (defined as eosinophils greater than 1,500/mm³ **OR** greater than 10% of leucocytes) – laboratory documentation must be provided
- iii. Two of the following – documentation from the medical record must be provided:
 - Biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation
 - Mononeuropathy or polyneuropathy
 - Nonfixed pulmonary infiltrates
 - Abnormalities of paranasal sinuses
- c. Member's symptoms remain uncontrolled or inadequately controlled despite treatment with oral corticosteroids
- d. Benralizumab is not used in combination with dupilumab (Dupixent), mepolizumab (Nucala), omalizumab (Xolair) or reslizumab (Cinqair)
- e. Benralizumab is prescribed by a board certified (or board eligible) allergist, immunologist, pulmonologist, or rheumatologist
- f. Dose does not exceed either of the following:
 - i. Initial dose: 30 mg every 4 weeks x 3 doses
 - ii. Maintenance dose: 30 mg every 8 weeks
- g. Member is 12 years of age or older

Approval duration: 12 months

Continuation of benralizumab (Fasenra) **meets the definition of medical necessity** when **ALL** of the following criteria are met:

1. Authorization/reauthorization has been previously approved by Florida Blue or another health plan in the past two years for treatment of severe eosinophilic asthma or EGPA, **OR** the member has previously met all indication-specific initiation criteria
2. **ONE** of the following:
 - a. Member has a beneficial response to treatment with benralizumab for severe eosinophilic asthma as demonstrated by at least **ONE** of the following and supported by documentation from the medical record:
 - i. Decreased frequency of exacerbations (defined as worsening of asthma that requires an increase in inhaled corticosteroid dose or treatment with systemic corticosteroids)
 - ii. Increase in predicted FEV1 from pretreatment baseline
 - iii. Reduction in reported asthma-related symptoms, such as, asthmatic symptoms upon awakening, coughing, fatigue, shortness of breath, sleep disturbance, or wheezing
 - b. Member achieves remission of EGPA
3. Benralizumab is prescribed by or in consultation with a board certified (or board eligible) allergist, immunologist, pulmonologist, or rheumatologist

4. Benralizumab is not used in combination with dupilumab (Dupixent), mepolizumab (Nucala), omalizumab (Xolair) or reslizumab (Cinqair)
5. Dose does not exceed 30 mg every 8 weeks

Approval duration: 12 months

DOSAGE/ADMINISTRATION:

THIS INFORMATION IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE USED AS A SOURCE FOR MAKING PRESCRIBING OR OTHER MEDICAL DETERMINATIONS. PROVIDERS SHOULD REFER TO THE MANUFACTURER'S FULL PRESCRIBING INFORMATION FOR DOSAGE GUIDELINES AND OTHER INFORMATION RELATED TO THIS MEDICATION BEFORE MAKING ANY CLINICAL DECISIONS REGARDING ITS USAGE.

FDA-approved

- 30 mg administered once every 4 weeks for the first 3 doses, and then once every 8 weeks thereafter by subcutaneous injection into the upper arm, thigh, or abdomen

Dose Adjustments

- None

Drug Availability

- Injection: 30 mg/mL solution in a single-dose prefilled syringe
- Injection: 30 mg/mL solution in a single-dose prefilled autoinjector

PRECAUTIONS:

Boxed Warning

- None

Contraindications

- Known hypersensitivity to benralizumab or excipients

Precautions/Warnings

- Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, rash)
- Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy; decrease corticosteroids gradually, if appropriate
- Parasitic (Helminth) Infection: Treat patients with pre-existing helminth infections before initiation of therapy; if patients become infected while receiving therapy and do not respond to anti-helminth treatment, discontinue until the parasitic infection resolve

BILLING/CODING INFORMATION:

The following codes may be used to describe:

HCPCS Coding

J0517	Injection, benralizumab, 1 mg
-------	-------------------------------

ICD-10 Diagnosis Codes That Support Medical Necessity

J82	Pulmonary eosinophilia, not elsewhere classified
M30.1	Polyarteritis with lung involvement [Churg-Strauss]

REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Part D: BCBSF has delegated to Prime Therapeutics authority to make coverage determinations for the Medicare Part D services referenced in this guideline.

Medicare Advantage: No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline review date. The Site of Care Policy for Select Specialty Medications does not apply to Medicare Advantage members.

DEFINITIONS:

FEV1:

- expiratory volume in 1 second

FVC:

- vital capacity

PEF:

- expiratory flow

Mild Intermittent Asthma:

- < or = to 2 times a week
- and normal PEF between exacerbations
- brief (from a few hours to a few days); intensity may vary
- symptoms < or = to 2 times a month
- or PEF > or = to 80% predicted
- variability < 20%

Mild Persistent Asthma:

- > 2 times a week but < 1 time a day

- may affect activity
- symptoms > 2 times a month
- or PEF > or = to 80% predicted
- variability 20 to 30 %

Moderate Persistent Asthma:

- symptoms
- symptoms > one time a week
- use of inhaled short-acting beta2-agonist
- may affect activity
- > or = to 2 times a week; may last days
- or PEF > 60% but less than 80% predicted
- variability > 30%

Severe Persistent Asthma:

- symptoms (i.e., coughing, dyspnea, wheezing)
- physical activity
- exacerbations
- nighttime symptoms
- or PEF < or = 60% predicted
- variability > 30%

RELATED GUIDELINES:

[Mepolizumab \(Nucala\), 09-J2000-54](#)

[Omalizumab \(Xolair®\), 09-J0000-44](#)

[Reslizumab \(Cinqair®\) IV infusion, 09-J2000-63](#)

OTHER:

Table 1 - Low, medium and high ICS doses: adults/adolescents (GINA 2020, Box 3-6A)

Inhaled Corticosteroid	Total daily ICS dose (mcg)		
	Low	Medium	High
Beclomethasone dipropionate (pMDI, standard particle, HFA)	200-500	>500-1000	>1000
Beclomethasone dipropionate (pMDI, extrafine particle, HFA)	100-200	>200-400	>400
Budesonide (DPI)	200-400	>400-800	>800
Ciclesonide (pMDI, extrafine particle, HFA)	80-160	>160-320	>320
Fluticasone furoate (DPI)	100	100	200
Fluticasone propionate (DPI)	100-250	>250-500	>500
Fluticasone propionate (pMDI, standard particle, HFA)	100-250	>250-500	>500
Mometasone furoate (DPI)	200	200	400
Mometasone furoate (pMDI, standard particle, HFA)	200-400	200-400	>400

DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; pMDI: pressurized metered dose inhaler (non-CFC)

Table 2 - Low, medium and high ICS doses: children 6-11 years (GINA 2020, Box 3-6B)

Inhaled Corticosteroid	Total daily ICS dose (mcg)		
	Low	Medium	High
Beclomethasone dipropionate (pMDI, standard particle, HFA)	100-200	>200-400	>400
Beclomethasone dipropionate (pMDI, extrafine particle, HFA)	50-100	>100-200	>200
Budesonide (DPI)	100-200	>200-400	>400
Budesonide (nebulas)	250-500	>500-1000	>1000
Ciclesonide (pMDI, extrafine particle, HFA)	80	>80-160	>160
Fluticasone furoate (DPI)	50	50	N/A
Fluticasone propionate (DPI)	50-100	>100-200	>200
Fluticasone propionate (pMDI, standard particle, HFA)	50-100	>100-200	>200
Mometasone furoate (pMDI, standard particle, HFA)	100	100	200
DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; pMDI: pressurized metered dose inhaler (non-CFC)			

Table 3 - Low, medium and high ICS doses: children 5 years and younger (GINA 2020, Box 3-6B)

Inhaled Corticosteroid	Total daily ICS dose (mcg)		
	Low	Medium	High
Beclomethasone dipropionate (pMDI, standard particle, HFA)	100-200	>200-400	>400
Beclomethasone dipropionate (pMDI, extrafine particle, HFA)	50-100	>100-200	>200
Budesonide (nebulas)	250-500	>500-1000	>1000
Ciclesonide (pMDI, extrafine particle, HFA)	N/A	N/A	N/A
Fluticasone furoate (DPI)	N/A	N/A	N/A
Fluticasone propionate (pMDI, standard particle, HFA)	100-200	>200-500	>500
Mometasone furoate (pMDI, standard particle, HFA)	100	100	200
DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; pMDI: pressurized metered dose inhaler (non-CFC)			

REFERENCES:

1. AHFS Drug Information. Bethesda (MD): American Society of Health-System Pharmacists, Inc; 2019 [cited 1/1/21]. In: STAT! Ref Online Electronic Medical Library [Internet]. Available from: <http://online.statref.com/>.
2. American Academy of Allergy Asthma and Immunology (AAAAI). AAAAI allergy & asthma medication guide. Available at: <http://www.aaaai.org/conditions-and-treatments/treatments/drug-guide/inhaled-corticosteroids.aspx>. Accessed 12/3/17.
3. American Academy of Allergy Asthma and Immunology (AAAAI). Conditions and treatments. Asthma. Available at: <http://www.aaaai.org>. Accessed on 12/3/17.
4. AstraZeneca. Fasentra (benralizumab) injection. 2017. [cited 12/3/17]. In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine. Available from: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da6aca1a-19ed-44a4-abb7-696c7d58b784>.
5. Bleeker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β_2 -agonists

(SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*. 2016 Oct 29;388(10056):2115-2127.

6. British Thoracic Society and Scottish Intercollegiate Guidelines Network (BTS/SIGN) national clinical guideline on management of asthma.
7. Centers for Disease Control and Prevention (CDC). Asthma FastStats. May 2015. Available at: <http://www.cdc.gov/nchs/faststats/asthma.htm>.
8. Clinical Pharmacology [Internet]. Tampa (FL): Gold Standard, Inc.; 2022 [cited 1/1/22]. Available from: <http://www.clinicalpharmacology.com/>.
9. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 Feb 29 - [cited 1/1/20]. Available from: <http://clinicaltrials.gov/>.
10. DRUGDEX® System [Internet]. Greenwood Village (CO): Thomson Micromedex; Updated periodically [cited 1/1/22].
11. European Respiratory Society/American Thoracic Society (ERS/ATS) guideline on definition, evaluation, and treatment of severe asthma. *Eur Respir J* 2014 Feb;43(2):343.
12. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2016 Oct 29;388(10056):2128-2141.
13. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, Global Initiative for Asthma (GINA) 2017. Available at: <http://www.ginasthma.org>. Accessed on 12/3/17.
14. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology and Joint Council of Allergy, Asthma and Immunology. Attaining optimal asthma control: a practice parameter. *J Allergy Clin Immunol*. 2005; 116(5):S3-S11.
15. Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. *N Engl J Med*. 2017 Jun 22;376(25):2448-2458.
16. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. NIH Publication Number 08-5846. Updated August 5, 2008. Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed on 12/3/17.
17. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report. *J Allergy Clin Immunol*. 2007 Nov;120(5 Suppl):S94-138.
18. National Heart, Lung and Blood Institute/National Asthma Education and Prevention Program (NHLBI/NAEPP). Guidelines for the Diagnosis and Management of Asthma (EPR-3). 2007. Available here: <http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines>
19. National Heart, Lung, and Blood Institute (NHLBI). National Institutes of Health (NIH). Health information for the public. Lung diseases. Available at: <http://www.nhlbi.nih.gov/health/>. Accessed on 12/3/17.
20. Orphan Drug Designations and Approval [Internet]. Silver Spring (MD): US Food and Drug Administration; 2022 [cited 1/1/22]. Available from: <http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm/>.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Pharmacy Policy Committee on 01/12/22.

GUIDELINE UPDATE INFORMATION:

01/15/18	New Medical Coverage Guideline.
02/15/18	Review of guideline; no changes.
06/15/18	Revision of guideline; updated ICD10 Codes.
01/01/19	Revision: HCPCS code updates. Added J0517 and removed J3590.
2/15/19	Review of guideline; updated position statement and references.
11/11/19	Revision to guideline consisting of adding a reference to the Site of Care Policy for Select Specialty Medications and updating the Program Exceptions.
2/15/19	Review of guideline; updated position statement, dosing, references.
02/15/21	Review of guideline; updated position statement and references.
02/15/22	Review of guideline; updated references.